语言版本

Time of issue:2021-09-02 16:56:33

中文 English





搜索

Search





Homepage

/

Product

/

API

All categories



Product name	CAS No.	Specification	Documentation
Acitretin	55079-83-9	EP/USP/in-house	DMF available
Acrivastine	87848-99-5	In-house	DMF available
Adapalene	106685-40-9	In-house	Technical Package available
Alitretinoin	5300-03-8	In-house	DMF available
Amino-polypeptide	107-71-1	In-house	Technical Package available
Anastrozole	120511-73-1	In-house	DMF preparation
Bendamustine HCl	3543-75-7	USP / in-house	DMF available
Benzoyl Peroxide	94-36-0	In-house	Technical Package available
Bepotastine Besilate	190786-44-8	In-house	Technical Package available
Betamethasone Dipropionate	5593-20-4	In-house	Technical Package available
Betamethasone Sodium Phosphate	151-73-5	EP /USP/in-house	Technical Package available
Bexarotene	153559-49-0	In-house	DMF available
Bilastine	202189-78-4	In-house	DMF preparation
Butinafine Hydrochloride	101827-46-7	In-house	Technical Package available
Calcipotriol	112965-21-6; 147657-22-5	EP / USP	DMF available
Calcium Levofolinate	80433-71-2	EP / JP	DMF available
Clobetasone Butyrate	25122-57-0	In-house	DMF preparation
Dapsone	80-08-0	In-house	Technical Package available
Desonide	638-94-8	In-house	Technical Package available
Dutasteride	164656-23-9	In-house	DMF preparation
Econazole Nitrate	24169-02-6	In-house	Technical Package available
Etoposide phosphate	117091-64-2	In-house	Technical Package available
Fluticasone propionate	80474-14-2	In-house	DMF preparation
Halometasone	50629-82-8	In-house	Technical Package available
Hydrocortisone Butyrate	13609-67-1	In-house	Technical Package available
Imiquimod	99011-02-6	In-house	Technical Package available
Isoniazid	54-85-3	In-house	Technical Package available
Isotretinoin	4759-48-2	EP / USP	DMF available
Itraconazole	84625-61-6	In-house	Technical Package available
Laurocapram	59227-89-3	In-house	Technical Package available
Levocetirizine HCl	130018-87-0	USP / in-house	DMF available
Linezolid	165800-03-3	USP / in-house	DMF available
Methoxsalen	298-81-7	In-house	Technical Package available
Methylprednisolone Hemisuccinate	2921-57-5	In-house	Technical Package available
Moxifloxacin HCl	186826-86-8	EP / USP	DMF available
Naftifine HCl	65473-14-5	USP	DMF available
Olopatadine HCl	140462-76-6	USP / JP	DMF preparation
Palonosetron HCl	135729-62-3	USP / in-house	DMF preparation
p-aminosalicylic acid	65-49-6	In-house	Technical Package available
Paricalcitol	131918-61-1	USP / in-house	DMF available
Pasiniazide	2066-89-9	In-house	Technical Package available
Penciclovir	39809-25-1	In-house	Technical Package available
Pyrazinamide	98-96-4	In-house	Technical Package available
Rifabutin	72559-06-9	In-house	Technical Package available
Rifapentine	61379-65-5	In-house	Technical Package available
Rivaroxaban	366789-02-8	In-house	DMF preparation
Roflumilast	162401-32-3	In-house	DMF available
Ruxotinib phosphate	1092939-17-7	EP / USP	DMF preparation
Tadalafil	171596-29-5	In-house	DMF preparation
Tazarotene	118292-40-3	In-house	DMF preparation
Terbinafine hydrochloride	78628-80-5	In-house	DMF preparation
Thymopentin	69558-55-0	In-house	Technical Package available
Tretinoin	302-79-4	EP/USP	DMF available
Valaciclovir hydrochloride	124832-27-5	In-house	Technical Package available
Viaminate	53839-71-7	In-house	Technical Package available

Fulvestrant

FASLODEX is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Number of views:

1000

Keywords:

treatment

disease

indicated

metastatic

in

for

progression

is

faslodex

Nintedanib esylate

Nintedanib esylate is a small molecule tyrosine kinase inhibitor with antifibrotic and anti-inflammatory activities for the treatment of idiopathic pulmonary fibrosis.

Number of views:

1000

Keywords:

small

treatment

for

pulmonary

is

the

with

fibrosis.

kinase

Ruxolitinib phosphate

Ruxolitinib phosphate is indicated for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis (PMF) (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis (PPV-MF), orpost-essential thrombocythemia myelofibrosis (PET-MF).

Number of views:

1000

Keywords:

myelofibrosis

known

Bendamustine HCl

Bendamustine HCl was originally manufactured in East Germany (former German Democratic Republic) in 1963.

Number of views:

1000

Keywords:

Bendamustine

treatment

Olopatadine HCl

Olopatadine HCl was developed by Kyowa Hakko Kirin, and it was first approved by the FOOD and Drug Administration (FDA) of the United States on December 18, 1996,

Number of views:

1000

Keywords:

Olopatadine

Patanol